Trial Profile
A study to evaluate the safety and pharmacokinetics of single and multiple doses of MK-1376
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Apr 2016
Price :
$35
*
At a glance
- Drugs MK 1376 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck & Co
- 27 Apr 2016 New trial record